問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
黃奕修
下載
2025-03-01 - 2026-12-31
Condition/Disease
It is used to treat inflammatory secondary macular edema (MESI) and is being explored as a treatment option for other retinal vascular diseases such as diabetic macular edema (DME).
Test Drug
KSI-101
Participate Sites3Sites
Recruiting3Sites
2020-09-01 - 2024-09-18
2020-12-01 - 2024-06-30
2023-01-01 - 2026-12-31
2021-11-01 - 2031-12-31
Participate Sites5Sites
Recruiting5Sites
2021-07-01 - 2027-12-31
2022-07-01 - 2024-09-20
Participate Sites16Sites
Not yet recruiting3Sites
Recruiting11Sites
Terminated2Sites
2024-02-01 - 2026-06-30
2024-12-01 - 2028-02-01
Participate Sites4Sites
Recruiting4Sites
2021-05-21 - 2024-06-30
全部
